OPP-ERA is implemented by a consortium of organizations committed to increase access to HIV-related diagnostics in developing countries. The OPP-ERA project is associating the interventions of an expertise agency, a global research agency and of two non-governmental organizations specialized in promoting access to health services in developing countries.
The Consortium is composed of the following organizations:
SOLTHIS - www.solthis.org
Solthis is an international solidarity NGO dedicated to improving prevention and access to quality health care. Solthis strengthens health systems and services in the countries where it operates. Solthis is comprised of committed health and development professionals who specialize in: a scientific and empirical approach that seeks cost-effective solutions adapted to realities in the field; mobilizing multidisciplinary experts from Northern and Southern nations in order to address all dimensions of health issues: medical, social, economic, or political.
In the context of the OPP-ERA project, Solthis implements the project in Guinea by supporting the Institut national de Santé Publique and the Hôpital de Donka in Conakry. Solthis is responsible for the general management of the project for phase 2 (2016-2019) in close collaboration with the other partners.
EXPERTISE FRANCE - www.expertisefrance.fr
Expertise France is the French international technical expertise agency. The aim of the agency is to increase the mobilization capacities of the various areas of public technical expertise in the international arena, in order to better respond to the growing needs of developing or emergent countries in terms of assistance to public policies. Under the joint tutelage of the Ministries of Foreign Affairs and Economy, the new agency fully bases its action within the framework of French foreign policy in the areas of development, solidarity, and influence. The agency intervenes in over 80 countries in this regard.
In the context of the OPP-ERA project, Expertise France is implementing the project through its local offices in Cameroun and Côte d'Ivoire for phases 1 & 2 and was responsible for the general management of the project in phase 1 (2013-2016).
SIDACTION - www.sidaction.org
Sidaction is a French non-profit organization gathering a collective of researchers, healthcare professionals and patients associations in France and in developing countries with the common goal of developing adapted scientific and medical research programs and providing support to prevention and assistance programs for people living with HIV/AIDS.
In the context of OPP-ERA, Sidaction implements the project in Burundi in close collaboration with the ANSS in Bujumbura.
ANRS - www.anrs.fr
is a French Research Agency on HIV and Viral Hepatitis which brings together researchers from different fields and institutions in the developed world and resource-limited countries to study scientific questions regarding HIV/AIDS and viral Hepatitis.
In the context of OPP-ERA, the ANRS provide its financial support as well as its scientific assistance to the project.
OPP-ERA is funded by UNITAID:
UNITAID - www.unitaid.eu
UNITAID is engaged in finding new ways to prevent, treat and diagnose HIV/AIDS, tuberculosis and malaria more quickly, more cheaply and more effectively. It takes game-changing ideas and turns them into practical solutions that can help accelerate the end of the three diseases. Established in 2006 by Brazil, Chile, France, Norway and the United Kingdom to provide an innovative approach to global health, UNITAID plays an important part in the global effort to defeat HIV/AIDS, tuberculosis and malaria, by facilitating and speeding up the availability of improved health tools, including medicines and diagnostics. UNITAID identifies health solutions that show promise and invests in them to establish their viability so that partner organisations can then make them widely available. By helping to fast-track access and reduce costs of new more effective medicines, technologies and systems UNITAID can maximize the impact of every dollar spent to overcome these lethal diseases. Many innovations championed by UNITAID and carried forward by our partners have had a big impact. Nearly 13 million people living with HIV are now on antiretroviral treatment, up from just 1.6 million in 2006, largely through a tenfold price reduction in medicines; there has been a 30 per cent year-on-year increase in detection of drug resistant TB in 2014, mostly due to the expanded use of innovative diagnostics; and malaria mortality has been halved since 2000, through better access to effective anti-malarial treatments and preventative measures such as mosquito nets.